Dosing & Administration
Your guide for the dosing and administration of VIDAZA® 1
Recommendation: Every patient should begin treatment at the same starting dose, regardless of haematological baseline values.1 Learn more about VIDAZA® dosing recommendations and the importance of monitoring for the need of dosing adjustments.
Preparation and Storage
Before administering VIDAZA®, the necessary supplies must be gathered and the suspension properly reconstituted.1 Read more about the proper way to prepare VIDAZA® for injection and instructions for storage of the suspension.
Injection Sites and Techniques
Learn tips on best injection sites and techniques to minimize skin irritation.
1. VIDAZA® Summary of Product Characteristics, 2011.
a. MDS-specific Indication
VIDAZA® is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with:
- intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
- chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
b. AML-specific Indication:
Treatment of adult AML patients who are not eligible for haematopoietic stem cell transplantation with 20-30% blasts and multi-lineage dysplasia, according to the WHO classification. WHO classifies RAEB-T patients with blasts ?20% to <30% as AML patients.
This is an international website for VIDAZA® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
The information on this website is based on the European Summary of Product Characteristics (SmPC). Please refer to your country-specific website, or contact a Celgene representative in your country for the latest information specific to your country.